Evaluation of vasopressin use in the management of refractory shock in patients admitted to the intensive care unit
DOI:
https://doi.org/10.33448/rsd-v11i9.32418Keywords:
Shock; Critical care; Intensive care units; Vasopressins; Norepinephrine; Vasoconstrictor agents.Abstract
Refractory shock is characterized by hemodynamic instability unresponsive to norepinephrine with a high mortality rate. As there are still doubts regarding the pharmacological benefit of the vasopressin addition, this retrospective study aimed to assess the profile of vasopressin use in the intensive care unit of a university hospital in Paraná, Brazil. The information collected was obtained through the analysis of electronic medical records. 73 patients with refractory shock, mainly of septic etiology (61.6%), were included. The dose (μg/Kg/minute) and duration of norepinephrine, upon finding refractoriness, was 35.6% infusion < 1, 34, 3% of 1-1.9, 30.1% > 2 and mean time of 1.5 days. High mortality (80.8%) was observed, with a mean hospital stay of 8.2 days. Median survival after vasopressin infusion was 4.5 days until the unfavorable outcome. Still, 80.5% of patients used other adjuvant therapy, 71.2% being corticotherapy and 9.6% dobutamine. Due to the great variability, it was not possible to define a pattern of use. There were limitations in the analysis due to the lack of clinical and prognostic information. However, the need for deepening scientific discussions and continuous updating of protocols that guide management is highlighted.
References
Annane, D., Ouanes-Besbes, L., de Backer, D., DU, B., Gordon, A. C., Hernández, G., Olsen, K. M., Osborn, T. M., Peake, S., Russell, J. A., & Cavazzoni, S. Z. (2018). A global perspective on vasoactive agents in shock. Intensive care medicine, 44(6), 833–846. https://doi.org/10.1007/s00134-018-5242-5
Barola S, Shabbir N. Refractory Shock. [Updated 2021 Oct 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564427/
Cui, N., Zhang, H., Chen, Z., & Yu, Z. (2019). Prognostic significance of PCT and CRP evaluation for adult ICU patients with sepsis and septic shock: retrospective analysis of 59 cases. The Journal of international medical research, 47(4), 1573–1579. https://doi.org/10.1177/0300060518822404
Duclos, G., Baumstarck, K., Dünser, M., Zieleskiewicz, L., & Leone, M. (2019). Effects of the discontinuation sequence of norepinephrine and vasopressin on hypotension incidence in patients with septic shock: A meta-analysis. Heart & lung : the journal of critical care, 48(6), 560–565. https://doi.org/10.1016/j.hrtlng.2019.05.007
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., Schorr, C., Simpson, S., Wiersinga, W. J., Alshamsi, F., Angus, D. C., Arabi, Y., Azevedo, L., Beale, R., Beilman, G., Belley-Cote, E., … Levy, M. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive care medicine, 47(11), 1181–1247. https://doi.org/10.1007/s00134-021-06506-y
Guinot, P.-G., Martin, A., Berthoud, V., Voizeux, P., Bartamian, L., Santangelo, E., Bouhemad, B., & Nguyen, M. (2021). Vasopressor-Sparing Strategies in Patients with Shock: A Scoping-Review and an Evidence-Based Strategy Proposition. Journal of Clinical Medicine, 10(14), 3164. https://doi.org/10.3390/jcm10143164
Hammond, D. A., Ficek, O. A., Painter, J. T., McCain, K., Cullen, J., Brotherton, A. L., Kakkera, K., Chopra, D., & Meena, N. (2018). Prospective Open-label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock. Pharmacotherapy, 38(5), 531–538. https://doi.org/10.1002/phar.2105
Huang, H., Wu, C., Shen, Q., Xu, H., Fang, Y., & Mao, W. (2021). The effect of early vasopressin use on patients with septic shock: A systematic review and meta-analysis. The American journal of emergency medicine, 48, 203–208. https://doi.org/10.1016/j.ajem.2021.05.007
Jentzer, J. C., Vallabhajosyula, S., Khanna, A. K., Chawla, L. S., Busse, L. W., & Kashani, K. B. (2018). Management of Refractory Vasodilatory Shock. Chest, 154(2), 416–426. https://doi.org/10.1016/j.chest.2017.12.021
Kądziołka, I., Świstek, R., Borowska, K., Tyszecki, P., & Serednicki, W. (2019). Validation of APACHE II and SAPS II scales at the intensive care unit along with assessment of SOFA scale at the admission as an isolated risk of death predictor. Anaesthesiology intensive therapy, 51(2), 107–111. https://doi.org/10.5114/ait.2019.86275
Kim, J. H., Sunkara, A., & Varnado, S. (2020). Management of Cardiogenic Shock in a Cardiac Intensive Care Unit. Methodist DeBakey cardiovascular journal, 16(1), 36–42. https://doi.org/10.14797/mdcj-16-1-36
Kislitsina, O. N., Rich, J. D., Wilcox, J. E., Pham, D. T., Churyla, A., Vorovich, E. B., Ghafourian, K., & Yancy, C. W. (2019). Shock - Classification and Pathophysiological Principles of Therapeutics. Current cardiology reviews, 15(2), 102–113. https://doi.org/10.2174/1573403X15666181212125024
Knotzer, H., Poidinger, B., & Kleinsasser, A. (2019). Pharmacologic Agents for the Treatment of Vasodilatory Shock. Current pharmaceutical design, 25(19), 2133–2139. https://doi.org/10.2174/1381612825666190704101907
Kny, K. T., Ferreira, M. A. P. & Pizzol, T. S. D. (2018). Use of vasopressin in the treatment of refractory septic shock. Revista Brasileira de Terapia Intensiva, 30(4), 423-428. Epub December 13, 2018.https://doi.org/10.5935/0103-507x.20180060
Mehta, S., Granton, J., Gordon, A. C., Cook, D. J., Lapinsky, S., Newton, G., Bandayrel, K., Little, A., Siau, C., Ayers, D., Singer, J., Lee, T. C., Walley, K. R., Storms, M., Cooper, D. J., Holmes, C. L., Hebert, P., Presneill, J., Russell, J. A., & Vasopressin and Septic Shock Trial (VASST) Investigators (2013). Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Critical care (London, England), 17(3), R117. https://doi.org/10.1186/cc12789
Meresse, Z., Medam, S., Mathieu, C., Duclos, G., Vincent, J. L., & Leone, M. (2020). Vasopressors to treat refractory septic shock. Minerva anestesiologica, 86(5), 537–545. https://doi.org/10.23736/S0375-9393.20.13826-4
Nakamura, K., Nakano, H., Naraba, H., Mochizuki, M., Takahashi, Y., Sonoo, T., Hashimoto, H., Abe, T., Hayakawa, M., & Yamakawa, K. (2021). Vasopressin Loading for Refractory Septic Shock: A Preliminary Analysis of a Case Series. Frontiers in medicine, 8, 644195. https://doi.org/10.3389/fmed.2021.644195
Patel, A., Beauchesne, A., Bredenkamp, N., McGloin, R., Stabler, S. N., & Boyce, K. (2020). Vasopressin for Septic Shock in a Medical-Surgical Intensive Care Unit. The Canadian journal of hospital pharmacy, 73(3), 209–21
Ríos-Toro, J. J., Márquez-Coello, M., García-Álvarez, J. M., Martín-Aspas, A., Rivera-Fernández, R., Sáez de Benito, A., & Girón-González, J. A. (2017). Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock. PloS one, 12(4), e0175254. https://doi.org/10.1371/journal.pone.0175254
Russell, J. A., Walley, K. R., Singer, J., Gordon, A. C., Hébert, P. C., Cooper, D. J., Holmes, C. L., Mehta, S., Granton, J. T., Storms, M. M., Cook, D. J., Presneill, J. J., Ayers, D., & VASST Investigators (2008). Vasopressin versus norepinephrine infusion in patients with septic shock. The New England journal of medicine, 358(9), 877–887. https://doi.org/10.1056/NEJMoa067373
Russell, J. A., Gordon, A. C., Williams, M. D., Boyd, J. H., Walley, K. R., & Kissoon, N. (2021). Vasopressor Therapy in the Intensive Care Unit. Seminars in respiratory and critical care medicine, 42(1), 59–77. https://doi.org/10.1055/s-0040-1710320
Standl, T., Annecke, T., Cascorbi, I., Heller, A. R., Sabashnikov, A., & Teske, W. (2018). The Nomenclature, Definition and Distinction of Types of Shock. Deutsches Arzteblatt international, 115(45), 757–768. https://doi.org/10.3238/arztebl.2018.0757
Thiele, H., Ohman, E. M., Desch, S., Eitel, I., & de Waha, S. (2015). Management of cardiogenic shock. European heart journal, 36(20), 1223–1230. https://doi.org/10.1093/eurheartj/ehv051
Udupa, A., & Shetty, R. (2018). Advanced cardiovascular support in refractory shock. Indian Journal of Respiratory Care, 7(2), 67. https://doi.org/10.4103/ijrc.ijrc_2_17
van Diepen, S., Katz, J. N., Albert, N. M., Henry, T. D., Jacobs, A. K., Kapur, N. K., Kilic, A., Menon, V., Ohman, E. M., Sweitzer, N. K., Thiele, H., Washam, J. B., Cohen, M. G., & American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. (2017). Contemporary management of cardiogenic shock: A scientific statement from the American heart association. Circulation, 136(16), e232–e268. https://doi.org/10.1161/CIR.0000000000000525
Wu, K. S., Gu, D. Y., Wang, T. T., Yu, B. W., Pan, K. H., & Zhou, J. C. (2020). Factors associated with outcomes of septic shock patients receiving high
dose noradrenaline according to three primary infection sites. The Journal of international medical research, 48(2), 300060519874545. https://doi.org/10.1177/0300060519874545
Wu, Z., Zhang, S., Xu, J., Xie, J., Huang, L., Huang, Y., Yang, Y., & Qiu, H. (2020). Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis. Shock (Augusta, Ga.), 53(1), 50–57. https://doi.org/10.1097/SHK.0000000000001345
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Julia Borges de Macedo; Edmar Miyoshi; Sinvaldo Baglie; Thomas Markus D'Haese
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
